Biopharmaceutical company Radius Health filed for an initial public offering on Tuesday that could raise up to $86.25m, less than two months after closing a $91m series D round. The major institutional shareholders in Radius are private equity firm MPM Capital (which holds 39.2% of Radius’ shares), medical foundation the Wellcome Trust (13.4%), venture capital…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
